Compugen(US:CGEN)2026-03-02 14:32Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth due to the $65 million upfront payment from AstraZeneca and other milestone payments [17][18] - R&D expenses for Q4 2025 were approximately $5.5 million, down from $5.9 million in Q4 2024, while total R&D expenses for the year were approximately $22.8 million, compared to $24.8 million in 2024, indicating a decrease primarily due to winding down prior clinical trials [18] - The company reported a net profit of approximately $56.8 million for Q4 2025, or approximately $0.60 per share, compared to a net loss of approximately $6.1 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with COM-701 showing promising results in the MAIA-ovarian trial [5][10] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million, indicating strong collaboration and financial prospects [12] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, supported by a non-dilutive transaction with AstraZeneca, which is crucial for funding ongoing and future clinical trials [4][16] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion, highlighting the market potential of the company's assets [8] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [10][14] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity, positioning the company for its next phase of growth [4][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for COM-701 to address significant unmet medical needs in ovarian cancer [10][33] - The company remains committed to leveraging its computational drug target discovery engine to deliver innovative immune oncology assets, supported by a solid financial outlook [14][15] Other Important Information - The company has diversified its leadership team and is focused on advancing its early-stage pipeline, which is managed by a large team [4][14] - The company retains the majority of its royalty interest in rilvegostomig, ensuring that its economic interests remain intact despite the recent monetization deal [6][7] Q&A Session Summary Question: What to expect in the 1Q 2027 update with COM-701? - Management indicated that the current trial is an adaptive design, and data maturation is expected in Q1 2027, with the timeline for registration depending on the totality of the data [23][24] Question: Cadence of potential milestones for rilvegostomig? - The next milestone payment is expected upon BLA acceptance, which will trigger an additional $25 million payment, with a total of $195 million in future milestones from AstraZeneca [27][28] Question: Shift in interim analysis timing for the ovarian trial? - The shift to Q1 2027 was due to slower opening of major academic sites, but all sites are now open, and the trial is on track [32][34] Question: Discussions on expanding the use of COM-902 derived TIGIT? - Management noted that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate as the company fully owns it [35] Question: Data expectations for GS-0321? - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety data [36]